Unsupervised stratification of patients with myocardial infarction based on imaging and in-silico biomarkers
Dolors Serra, Pau Romero, Paula Franco, Ignacio Bernat, Miguel Lozano, Ignacio Garcia-Fernandez, David Soto, Antonio Berruezo, Oscar Camara, Rafael Sebastian
TL;DR
Post-MI ventricular tachycardia risk prediction is challenging; this work combines LGE-CMR-derived 3D cardiac anatomy with a fast cellular automaton (Arrhythmic3D) to simulate thousands of VT scenarios per patient. ARRISK, a normalized AR-index derived from simulation results, stratifies patients into ZERO/LOW/HIGH risk and correlates with clinical outcomes, often outperforming imaging-based risk markers. Biophysical validation with openCARP confirms the consistency of predicted exit sites and reentry circuits. The approach enables automated, rapid, patient-specific risk assessment suitable for clinical workflows and may guide targeted ablation strategies.
Abstract
This study presents a novel methodology for stratifying post-myocardial infarction patients at risk of ventricular arrhythmias using patient-specific 3D cardiac models derived from late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) images. The method integrates imaging and computational simulation with a simplified cellular automaton model, Arrhythmic3D, enabling rapid and accurate VA risk assessment in clinical timeframes. Applied to 51 patients, the model generated thousands of personalized simulations to evaluate arrhythmia inducibility and predict VA risk. Key findings include the identification of slow conduction channels (SCCs) within scar tissue as critical to reentrant arrhythmias and the localization of high-risk zones for potential intervention. The Arrhythmic Risk Score (ARRISK), developed from simulation results, demonstrated strong concordance with clinical outcomes and outperformed traditional imaging-based risk stratification. The methodology is fully automated, requiring minimal user intervention, and offers a promising tool for improving precision medicine in cardiac care by enhancing patient-specific arrhythmia risk assessment and guiding treatment strategies.
